Wu et al. (2011) |
Inflammation |
C57BL mice (Female, 4/4, 8-10 weeks) |
LPS((1mg/kg) |
Gavage, ICT, 25/50/100mg/kg/d, 3 days |
Gavage,
H2O, 3 days |
① |
Li et al. (2014) |
Inflammation |
BALB/c mice (Male, 10/10, 6 weeks) |
Cigarettes (15 mg nicotine and 195 mg tar, 3 month) |
Gavage,
ICA,25/50/100mg/kg/d, 90 days |
No procedures |
①⑤ |
Hu et al. (2016) |
Atherosclerosis (AS) |
Wistar rats (Male, 7/7,
180-220 g) |
High-cholesterol diet (HCD, 83.8 %
normal diet,
3.5 % cholesterol, 10 % animal oil, 0.2
%
propylthiouracil, 0.5 % sodium cholate, and 5
%
refined sugar, 9 weeks)
|
Gavage, ICA,30/60mg/kg/d, 28
days |
No mention |
①③⑩⑪ |
Fu et al. (2018) |
Myocardial fibrosis |
Spontaneously hypertensive
rats:SHRs(Male, 10/20, 13 weeks) |
Spontaneously hypertensive rats |
Gavage, ICS II, 4/8/16mg/kg/d, 84 days |
Gavage, distilled water, 84
days |
①②③④⑤ |
Su et al. (2018) |
Lupus nephritis (LN) |
MRL/lpr mice (10/10, 10 weeks) |
MRL/lpr mice |
Gavage, ICA, 10mg/kg/d, 56 days |
Gavage, saline, 56
days |
①②⑨⑬ |
Zhang et al. (2017) |
IgA nephropathy |
SD rats (Male, 15/15, 6 weeks,
180-200 g) |
0.1% BGG (8 weeks) |
Gavage, ICA, 10mg/kg/d, 42 days |
Gavage, saline, 42 days |
②④⑤⑧⑨⑬ |
Ma et al. (2015) |
Acute renal injury |
BALB/c mice (Male, 10/10, 20-22
g) |
Cisplatin (15 mg/kg) |
Gavage, ICA, 30/60mg/kg/d, 5 days |
Gavage,
saline, 5 days |
⑩⑪⑭ |
Guo et al. (2010) |
Brain dysfunction |
SD rats (Male, 14/14, 10-14
weeks, 250-300 g) |
LPS (10μl) |
Gavage, ICA, 30/60/120mg/kg/d, 17 days |
Gavage, distilled water, 17 days |
①② |
Xiong et al. (2016) |
Cerebral I/R |
SD rats (Male, 5/5, 16 weeks,
250-280 g) |
Reperfusion after MACO (24h) |
Gavage, ICA, 10/30mg/kg/d, 3
days |
Gavage, saline, 3 days |
②④⑤⑥⑦ |
Deng et al. (2016) |
Cerebral I/R |
SD rats (Male, 5/5, 250-280 g) |
Reperfusion after MACO (24h) |
Gavage, ICS II, 10/30mg/kg/d, 3 days |
Gavage, saline, 3 days |
②④⑤⑥⑦⑧ |
Li et al. (2018) |
SCI |
C57BL mice (Male, 6/6, 8 weeks) |
Spinal cord
after laminectomy |
Gavage, ICA, 13.53/33.84mg/kg/d, 3 days |
Gavage,
saline, 3 days |
①②⑩⑪⑭⑮ |
Xu et al. (2010) |
Acute lung inflammatory |
C57BL mice (Male, 8/8,
11-12 weeks, 22-24 g) |
LPS (5 mg/ kg) |
Intraperitoneal injection,
ICA,
20mg/kg/d, 0.25 days
|
Intraperitoneal injection, PBS
(Phosphate
Buffered Saline), 0.25 days
|
① |
Wei et al. (2015) |
Asthma |
BALB/c mice (Female, 20/20,12-16 g) |
3%
OVA ovalbumin (21 days) |
Gavage, ICA, 20/50/100mg/kg/d, 56 days |
Gavage, saline, 56 days |
③④ |
Xie et al. (2018) |
Acute kidney injury |
C57BL mice (Male, 10/10, 38-44
weeks) |
cecal ligation and perforation (CLP) |
Intraperitoneal
injection, ICA, 30/60mg/kg/d, 3 days |
No mention |
①②③⑩⑪⑭⑮ |
Zhang et al. (2015) |
Intestinal I/R |
SD rats (Male, 8/8, 180-220 g) |
ischemiaereperfusion (I/R) |
Gavage, ICA, 30/60mg/kg/d, 3 days |
Gavage,
0.1% DMSO, 3 days |
①③⑩⑭ |
Shao et al. (2015) |
Osteolysis |
C57BL mice (Male, 21/21, 7-8 weeks) |
20 mg Ti particle |
Gavage, ICA,100/300mg/kg/d, 14 days |
Gavage,
saline, 14 days |
①②③ |
Tao et al. (2013) |
Colitis |
C57BL mice (Female, 6/6, 8 weeks, 19-20
weeks) |
2.5% dextran sulfate sodium DSS (7 days) |
Gavage,
ICA,3/10mg/kg/d, 10 days, |
Gavage, drinking water, 10 days |
①⑫ |
Zhang et al. (2018) |
Periodontitis |
Mini pig (Female, 6/6) |
Alveolar
bone defects |
Local injection, ICA,0.1 μg/mL, 84 days |
Local
injection, saline, 84 days |
②⑫ |
Zhou et al. (2011) |
Tumor |
BALB/c mice (Female, 5/5, 6-8 weeks) |
Tumor inoculation |
Intraperitoneal injection, ICA, 100mg/kg/d |
No
mention |
⑫ |